Patients were assigned to receive 2.5 g/d of metformin plus placebo ( n = 116 ) ; 2.5 g/d of metformin plus 4 mg/d of rosiglitazone ( n = 119 ) ; or 2.5 g/d of metformin and 8 mg/d of rosiglitazone ( n = 113 ) for 26 weeks .
